- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03139084
Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension (BOTA-PAH)
An Observational, Non-interventional, Multicenter Study to Evaluate the Efficacy and Safety of Upfront Combination of Bosentan and Tadalafil in Pulmonary Arterial Hypertension in Greek Patients
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The primary objective of BOTA study is to compare the change in clinical and hemodynamic measures of PAH after the initiation of first line combination therapy with bosentan and tadalafil in adult patients with PAH. The safety and tolerability of first line combination therapy will also be evaluated.
In patients with PAH initial upfront combination treatment with bosentan and tadalafil
Improves
- Exercise capacity as expressed by distance walked in six minute walk test and WHO functional class
- Hemodynamics in terms of pulmonary vascular resistance (PVR), mean pulmonary artery pressure (mPAP) reduction and cardiac index (CI) elevation
- Quality of life
- NTproBNP serum levels
- Echocardiographic prognostic parameters such as right atrial area and presence of pericardial effusion.
Is safe as assessed by
- Liver function markers such as serum SGOT and SGPT levels
- Hemoglobin levels
Studietyp
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
Male or females between 18 to 75 years of age at inclusion
Diagnosis of PAH due to the following:
- Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)
- Hereditary PAH
- PAH secondary to connective tissue disease
- PAH diagnosis confirmed by right heart catheterization performed within 3 months prior to study enrolment Subjects must weigh at least 40 kg at inclusion Subject must have a current diagnosis of being in World Health Organisation (WHO) Functional Class II or III.
Treatment PAH naïve subjects PAH documented by
- mPAP ≥25mmHg,
- pulmonary capillary wedge pressure (PCWP) or
- left ventricular end-diastolic pressure (LVEDP) ≤15mmHg and
- PVR ≥3 Wood Units. Subject must walk a distance of ≥125m and ≤500m at the screening visit
Exclusion Criteria:
- History of pulmonary embolism
- No prior treatment with PDE-5 inhibitors
- History of chronic lung disease / restrictive lung disease (eg, chronic obstructive pulmonary disease (COPD) or scleroderma) with impairment of lung function
- Current treatment with nitrates or nitric oxide
- Significant (ie, >2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation
- History of cardiac arrest, respiratory arrest, hemodynamic collapse, CPR, ventricular tachycardia, ventricular fibrillation, or uncontrolled atrial fibrillation
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Month 6
Tidsram: 6 months
|
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is a surrogate marker of heart failure.
The geometric mean ratio will be calculated as the ratio between the month 6 value and the Baseline value and presented as percent change = 100 * (geometric mean ratio - 1).
The Baseline value is the last value prior to administration of study drug; this may be prior to or on the day of study drug initiation.
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With First Adjudicated Clinical Failure (CF) Event
Tidsram: 6 months
|
Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Clinical Response
|
6 months
|
Time to first clinical worsening (TTCW) event
Tidsram: 6 months
|
TTCW defined as the number of days between first dose of study drug and the occurrence of a predefined clinical worsening event.
|
6 months
|
Percentage of Participants With a Satisfactory Clinical Response at Month 6
Tidsram: 6 months
|
A satisfactory clinical response at month 6 is defined as a participant who meets all of the following criteria: 10% improvement in 6MWD compared with Baseline;
|
6 months
|
Change From Baseline in the World Health Organization Functional Class at month 6
Tidsram: 6 months
|
Change From Baseline in the World Health Organization Functional Class Time Frame: Baseline and Month 6 The WHO Functional Class (FC) indicates the severity of PAH and is an adaptation of the New York Heart Association classification.
|
6 months
|
Change From Baseline in the 6 Minute Walk Distance (6MWD) Test at month 6
Tidsram: 6 months
|
Change From Baseline in the 6 Minute Walk Distance (6MWD) Test at month 6 MWD is the distance a participant can walk in 6 minutes. The 6-minute walk distance (6MWD) test measures the distance that a participant can walk in a period of 6 minutes. |
6 months
|
Change From Baseline in Borg Dyspnea Index at month 6
Tidsram: 6 months
|
Borg Dyspnea Index (BDI) indicates the degree of breathlessness after completion of the 6 minute walk test.
|
6 months
|
Quality of Life
Tidsram: 6 moths
|
Change in emPHasis-10 questionnaire score
|
6 moths
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. No abstract available.
- Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
- McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2017-BSN-EL-73
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Pulmonell hypertoni
-
Biodesix, Inc.AvslutadNSCLC | Nodule Solitary PulmonaryFörenta staterna
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Avslutad
-
Biodesix, Inc.RekryteringIcke-småcelligt karcinom | Nodule Solitary PulmonaryFörenta staterna, Kanada
-
NovartisAvslutad
-
Beijing Aerospace General HospitalAvslutadSutur | Videoassisterad torakoskopisk kirurgi | Nodule, Solitary PulmonaryKina
-
NovartisAvslutadMETABOLISKT SYNDROM | HYPERTENSION | PRE-HYPERTENSIONFörenta staterna
-
Centre Chirurgical Marie LannelongueOkändKronisk trombo-embolisk pulmonell hypertension och pulmonell arteriell hypertensionFrankrike
-
NovartisAvslutadHYPERTENSION | HYPERKOLESTEROLEMIFörenta staterna
-
University of California, San FranciscoNorthern California Institute of Research and Education; Guardant Health...RekryteringIcke-småcellig lungcancer | Nodule Solitary PulmonaryFörenta staterna